GYNORYLAQ™-VLINIVAL™: Ψ-Guided Personalized Neoantigen Peptide Vaccine for High-Risk Endometrial Cancer
Clinical trial NCT07316361 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT07316361
- Sponsor
- Biogenea Pharmaceuticals Ltd.
- Status
- ENROLLING_BY_INVITATION
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-02-02
- Primary completion
- 2029-12-02
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.